Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0360320000320040682
Journal of Korean Cancer Research Association
2000 Volume.32 No. 4 p.682 ~ p.689
Concurrent Chemoradiation Therapy with Cisplatin and Oral Etoposide for Locally Advanced Non-small Cell Lung Cancer
1¹éâ¿ø/1Chang Won Paek
1À±¼Ò¿µ/1¼­ÀçÈ«/1ÃÖö¿ø/1±èº´¼ö/1½Å»ó¿ø/1±è¿­È«/1½ÉÀçÁ¤/1°­°æÈ£/1±èÁؼ®/2±èö¿ë/2ÃÖ¸í¼±/3ÃÖ¿µÈ£/3±è±¤ÅÃ/1So Young Yoon/1Jae Hong Seo/1Chul Won Choi/1Byung Soo Kim/1Sang Won Shin/1Yeul Hong Kim/1Jae Jung Shim/1Kyung Ho Kang/1Jun Suk Kim/2Chul Yong Kim/2My
Abstract
-Abstract-
Purpose: Prognosis of locally advanced inoperable non-small cell lung cancer (NSCLC)
treated with radiation therapy alone has been disappointing. In recent years, concurrent
chemoradiation therapy has potential of improving both local and metastatic disease-free
survival. This phase¥± study was undertaken to determine the feasibility, toxicity,
response rate, local control rate, and survival duration of locally advanced NSCL patients
treated with concurrent chemoradiation using cisplatin and oral etoposide.
Materials and Methods: Forty-seven patients were enrolled and forty-one patients were
evaluable. Chemotheray consisted of cisplatin 50 §·/§³/¥³ on days 1 and 8 and oral
etoposide 100§·/day on days 1 to 5 and 8 to 12 which was repeated, every 4 weeks for
two cycles during radiation therapy. Radiation therapy was administered to a total dose
of 6300 cGY.
Results: Among 41 evaluable patients, six patients achieved complete response, and
twenty had partial response, for an overall response rate of 63.4% (95% confidence
interval; 48.4% to 75.4%). Stable disease was reported in 10 patients (24.4%) and
another 5 (12.2%) showed disease progression. Overall survival rate was 76% at 1 year,
34% at 2 years. Median survival duration was 17 months (range; 3 + to 41 +).
Eighty-three percents of patients had radiation pneumonitis but only one patients needed
medical treatment.
Conclusion: concurrent chemoradiation therapy with cisplatin and oral etoposide at this
level is a well tolerated and feasible.
KEYWORD
FullTexts / Linksout information
 
Listed journal information
KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø